ALM Guideline Template Ver7.0
ALM Guideline Template Ver7.0
8 TITLE:
10 ABSTRACT
12
13 Key Words: Key word 1, Key word 2, Key word 3 [List three to ten pertinent keywords to
15 (http://www.nlm.nih.gov/mesh/ MBrowser.html)].
16
1 1
2
17 INTRODUCTION
18 The introduction of the study should provide a concise overview of its context and emphasize
19 its significance. It should clarify the purpose of the work and its importance. A thorough
20 examination of the current state of research in the field should be conducted, with relevant
21 publications being referenced. Briefly mention the main objective of the study and emphasize
22 its principal conclusions at the end. There is no limit of the length of the manuscript.
23
24
25 HEADING 1
26 Sub-heading 1
27 References should be cited numerically in square brackets, such as [1] or [2,3], or as a range
28 [4–6]. The name of a microorganism should be spelled out the first mention in the abstract,
29 and original text. The names of the genus can be abbreviated subsequently (example: E. coli).
30 The names of the genes, and not the proteins should be italicized: BCR-ABL mutations,
31 HER2-positive.
32
33 Sub-heading 2
36 approved by the Research Ethics Committee or the Institutional Review Board (IRB) of the
37 institution where the experiment was performed. Written informed consent should be
38 obtained from all subjects, when necessary. Statistical methods should be described with
3 2
4
39 software program in detail.
40
41 HEADING 2
42 Sub-heading 1
43 There is no limit of the number of Tables or Figures. All sections of the results should
44 refer to a figure (for example, Fig. 1) or table (for example, Table 1), preferably a data
45 display element that is part of the main text. All figures, figure panels and tables must be
46 presented in order. Figures or tables too large for print, manuscript material that exceeds the
47 limitation for the specific submission type, or appendices should be submitted for online
48 publication only. These files should be marked and uploaded separately as supplemental files
49 during submission and should be referenced within the text as supplemental data (i.e., “See
50 Supplemental Data Table S1”, “See Supplemental Data Figure S1”, etc.).
51
52 Sub-heading 2
53 Equations can be included. Use MathType (recommended) or use the legacy equation editor
54 in Word (Chose Insert > Insert Object > Word Equation). P is the proportion and N is the
55 number of samples.
56
57 ACKNOWLEDGMENTS
58 None
59
5 3
6
60 AUTHOR CONTRIBUTIONS
63
64 Conceptualization:
65 Methodology:
66 Investigation:
67 Visualization:
68 Funding acquisition:
69 Project administration:
70 Supervision:
73
74 CONFLICTS OF INTEREST
75 Include any financial interests for each author that could be perceived as being a conflict of
76 interest (i.g. sources of support, consulting fee or honorarium, support for travel to meetings
77 for the study or other purposes, fee for participation in review activities such as data
78 monitoring boards, payment for writing the manuscript, provision of writing assistance or
79 equipment, board membership, patents, royalties, monetary interests in the products studied,
7 4
8
80 consultantships, stocks, etc.). When authors have no competing interests, this should also be
82
83 RESEARCH FUNDING
85 or None.
86
87 REFERENCES
88 1. Ann Lab Med uses “Vancouver” style, as outlined in the ICMJE sample references.
90 tables and legends) and listed individually at the end of the manuscript. There is no limit
91 of the number of References. Each entry starts with the author’s last name and initials.
92 When a source has more than one author, their names are separated by commas. If a
93 source has more than six authors, list the first six followed by ‘et al.’
96 3. Garratty G and Petz LD. Approaches to selecting blood for transfusion to patients
98 4. Helms CC, Marvel M, Zhao W, Stahle M, Vest R, Kato GJ, et al. Mechanisms of
100
101
9 5
10
102 Tables
*
104 Tables may have footnotes.
†
105 Tables may have footnotes.
‡
106 Tables may have footnotes.
§
107 Tables may have footnotes.
108 Abbreviations: NT, not tested and SAA, severe aplastic anemia.
109
11 6
12
110 Figures
111
112 Fig. 1. Short title of the figure. (A), explanation and (B), explanation. *P < 0.05, †P < 0.001,
13 7
14
115 Supplemental Data
116
117 Supplemental Data Table S1. Short title of the first table
118
119
120 Supplemental Data Figure S1. Short title of the first figure
15 8
16